Related references
Note: Only part of the references are listed.Population Pharmacokinetics of Melphalan and Glutathione S-transferase Polymorphisms in Relation to Side Effects (vol 83, pg 749, 2008)
A. Kuehne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Prospective Oral Mucositis Audit: Oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy - European blood and marrow transplantation mucositis advisory group
Nicole Blijlevens et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects
A. Kuehne et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs
Richard M. Logan et al.
CANCER TREATMENT REVIEWS (2007)
Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis
N. Blijlevens et al.
ANNALS OF ONCOLOGY (2007)
Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies
Montserrat Vera-Llonch et al.
SUPPORTIVE CARE IN CANCER (2007)
Updated clinical practice guidelines for the prevention and treatment of mucositis
Dorothy M. Keefe et al.
CANCER (2007)
Management of oral mucositis at European transplantation centres
Rebecca Stone et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2007)
Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit
Barry Quinn et al.
EUROPEAN JOURNAL OF ONCOLOGY NURSING (2007)
Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting
Patrick J. Stiff et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies
S. R. Fanning et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model
M. L. Grazziutti et al.
BONE MARROW TRANSPLANTATION (2006)
Palifermin for oral mucositis after intensive therapy for hematologic cancers
R Spielberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The burdens of cancer therapy - Clinical and economic outcomes of chemotherapy-induced mucositis
LS Elting et al.
CANCER (2003)
Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy
E Tsuji et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients
RL Lark et al.
CLINICAL INFECTIOUS DISEASES (2001)
Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue
AM Wardley et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview
NMA Blijlevens et al.
BONE MARROW TRANSPLANTATION (2000)
Share Paper
